Genentech/Biogen Idec Submit Rituxan sBLA For Front-Line Non-Hodgkin’s Lymphoma

Expanded indication could be approved by February 2006, contingent upon a requested priority review.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet